Literature DB >> 23149624

Current concepts in refractory migraine.

Elliott Schulman1, Brian E McGeeney.   

Abstract

OPINION STATEMENT: The Refractory or Intractable Migraine (RM) patient has long been a challenge to all healthcare providers (HCP). Headache specialists have recognized this sub group of patients who remain refractory to treatment. Despite this recognition, there are no formal criteria that characterize RM. This article will attempt to provide treatment approaches, some scientifically based and others that are empiric. A reasonable goal is to lessen disability. Combining the various modalities will improve the chances for successful treatment. The foundation of treatment is an emphasis on wellness. This includes optimizing mood, minimizing stress, practicing good sleep hygiene, and avoiding triggers. All comorbid factors should be addressed, including sleep and mood disorders, chronic neck pain, and obesity. Preventive treatment is necessary in the majority of patients, and a plan for "rescue" approaches is essential. Avoiding medication overuse, particularly narcotics, is advisable. Additional options for treatment include onabotulinumtoxinA, and more invasive modalities, such as neurostimulation. Adjunct treatment including supplements and relaxation may also be considered. Keeping a headache calendar is almost mandatory in management with attention to particular headache triggers, patterns and medication overuse (MOH). A trusting physician-patient relationship is also very important and will enhance compliance and foster communication. Patients often lapse from the management plan and the treating physician should be open minded about continuing care. RM is a long-term disease and requires close physician-patient interaction and cooperation for management of the problem. In those RM patients with multiple comorbidities, a multidisciplinary team should optimize management.

Entities:  

Year:  2013        PMID: 23149624     DOI: 10.1007/s11940-012-0206-5

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  41 in total

1.  Low-dose caffeine physical dependence in humans.

Authors:  R R Griffiths; S M Evans; S J Heishman; K L Preston; C A Sannerud; B Wolf; P P Woodson
Journal:  J Pharmacol Exp Ther       Date:  1990-12       Impact factor: 4.030

2.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

3.  Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache.

Authors:  J Jones; D Sklar; J Dougherty; W White
Journal:  JAMA       Date:  1989-02-24       Impact factor: 56.272

Review 4.  Increased prevalence of sleep disorders in chronic headache: a case-control study.

Authors:  Elisa Sancisi; Sabina Cevoli; Luca Vignatelli; Marianna Nicodemo; Giulia Pierangeli; Stefano Zanigni; Daniela Grimaldi; Pietro Cortelli; Pasquale Montagna
Journal:  Headache       Date:  2010-10       Impact factor: 5.887

5.  Sleep and headache.

Authors:  Jeanetta C Rains; J Steven Poceta
Journal:  Curr Treat Options Neurol       Date:  2010-01       Impact factor: 3.598

6.  Repetitive intravenous dihydroergotamine as therapy for intractable migraine.

Authors:  N H Raskin
Journal:  Neurology       Date:  1986-07       Impact factor: 9.910

Review 7.  The stress and migraine interaction.

Authors:  Khara M Sauro; Werner J Becker
Journal:  Headache       Date:  2009-07-08       Impact factor: 5.887

8.  Childhood maltreatment and migraine (part I). Prevalence and adult revictimization: a multicenter headache clinic survey.

Authors:  Gretchen E Tietjen; Jan L Brandes; B Lee Peterlin; Arnolda Eloff; Rima M Dafer; Michael R Stein; Ellen Drexler; Vincent T Martin; Susan Hutchinson; Sheena K Aurora; Ana Recober; Nabeel A Herial; Christine Utley; Leah White; Sadik A Khuder
Journal:  Headache       Date:  2009-10-21       Impact factor: 5.887

9.  Childhood maltreatment and migraine (part III). Association with comorbid pain conditions.

Authors:  Gretchen E Tietjen; Jan L Brandes; B Lee Peterlin; Arnolda Eloff; Rima M Dafer; Michael R Stein; Ellen Drexler; Vincent T Martin; Susan Hutchinson; Sheena K Aurora; Ana Recober; Nabeel A Herial; Christine Utley; Leah White; Sadik A Khuder
Journal:  Headache       Date:  2009-10-21       Impact factor: 5.887

10.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292

View more
  2 in total

1.  Refractory migraine: the role of the physician in assessment and treatment of a problematic disease.

Authors:  Bruno Colombo; Dacia Dalla Libera; Gloria Dalla Costa; Giancarlo Comi
Journal:  Neurol Sci       Date:  2013-05       Impact factor: 3.307

Review 2.  Tackling chronic migraine: current perspectives.

Authors:  Francisco Javier Carod-Artal
Journal:  J Pain Res       Date:  2014-04-08       Impact factor: 3.133

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.